Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

These reports, excerpted and edited by Barron's, were issued recently by investment and research firms. The reports are a sampling of analysts' thinking; they should not be considered the views or recommendations of Barron's.

Novartis Looks Appealing, Based on Strong Drug Pipeline and Planned Sandoz Spinoff

Novartis CEO Vas Narasimhan could struggle to woo investors to the listing of generics drugs business Sandoz, as weaker drug prices and jittery financial markets present one of his biggest challenges in the years-long overhaul of the Swiss drugmaker.

Analysis-Novartis CEO may struggle to rally investors to Sandoz spin-off

In the event of a recession, this is a stock that can potentially do better than the market, and so far it has already proven that. Novartis' dividend currently has a dividend yield (FWD) of 3.98%, much higher than the industry average of 2.28%. What's more, this dividend is absolutely sustainable.

Novartis: Undervalued And Trustworthy

Novartis (NVS) is set to spin off Sandoz into a new publicly traded standalone company to focus better on its core pharmaceutical business.

Novartis (NVS) Plans to Spin Off Generics Business Sandoz

Novartis AG is planning to spin off its generics-and-biosimilars division Sandoz and list it as a standalone company in Switzerland, a move that will enable Novartis to focus on innovative medicines.

Novartis to spin off, list Sandoz business

Novartis said on Thursday it would spin off Sandoz and list it on the Swiss stock exchange to create the No.1 European generics company.

Novartis to spin off Sandoz, list it in Zurich

Sandoz strategic review concludes that a separation of Sandoz by way of a 100% spin-off is in the best interest of shareholders, creating the #1 European generics company and a global leader in biosimilars, and a more focused Novartis

Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off

Aerie Pharmaceuticals

Alcon Inc. - Registered Shares

Most investors would probably be pleased with a share price gain of 33% in just over three years, but more than 50% sounds a lot better.

Don't Look for Alcon's Acquisition to Boost Share Price in Short Term

British American Tobacco

Enbridge

Altria

Merck

The 4th bear market rally appears to have failed and if history and fundamentals are any guides, the market might have 16% to 27% further to fall. This was 100% expected by every student of market history, who knew to expect a 16.2% bear market rally that wouldn't last (17.5% peak rally, and now stocks are crashing).

7 High-Yield Dividend Aristocrats For The Next Market Crash

Novartis is a global healthcare company with a research-driven focus on pharmaceuticals, both prescription-based and generic. Valued at a one-year forward P/E of < x14, Novartis trades at a discount to fair value, in my opinion.

Novartis: Undervalued Swiss Pharma Giant

Novartis (NVS) suffers a setback as canakinumab fails to meet the primary goal in yet another study for lung cancer.

Novartis (NVS) NSCLC Study Fails to Meet Primary Endpoint

Basel, August 15, 2022 — Novartis announced today that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab (ACZ885), an inhibitor of interleukin-1beta (IL-1β), in adult patients with stages II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) did not meet its primary endpoint of disease-free survival (DFS) versus placebo1. No unexpected safety signals were observed.1 Findings from the trial will be presented at an upcoming medical meeting.

Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer

Novartis is one of the most dominant pharma companies in the world.

Here's Why Income Investors Should Consider Buying This High-Yield Dividend Stock

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said it has entered into a commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc for the Canadian commercialization of two innovative ophthalmic therapies. Under the agreement, Valeo becomes the exclusive distributor of XIIDRA (lifitegrast) and SIMBRINZA (brinzolamide / brimonidine tartrate) in Canada, making it responsible for all commercial and medical activities.

Valeo Pharma enters commercialization and supply agreement with Novartis Canada for two ophthalmic therapies

BERKELEY, Calif.--(BUSINESS WIRE)--Novartis and the University of California, Berkeley have extended their research-based collaboration to develop new technologies for the discovery of next-generation therapeutics, following its successes over the last five years. The combined research team is pursuing a vast number of disease targets in cancer and other illnesses that have eluded traditional small-molecule compounds and drug discovery strategies. “One of the biggest challenges facing drug disc

Novartis and UC Berkeley Extend Alliance to Tackle 'Undruggable' Disease Targets and Discover New Therapeutic Modalities

The FDA defers action on a highly anticipated potential blockbuster drug for cancer.

What This FDA Delay Means for Novartis

Black Hills

Clorox

Fresenius Medical Care

Medtronic

MDU Resources Group

National Fuel Gas

Northwest Natural Gas

Philip Morris

Fears of a recession are mounting, with BAC and Deutsche Bank now forecasting a mild downturn in 2023. A recession could even begin by December 2022. Even without a recession Morgan Stanley is confident stocks have 10% lower to fall. If we get a mild recession, stocks could fall 25% more and in a severe recession, 35%.

11 High-Yield Dividend Aristocrats Perfect For The Coming Recession

Swiss drugmaker Novartis delivered a mixed second-quarter report Tuesday, but Novartis stock popped on the company's bullish outlook. The post How Novartis' Laggard Business Was Its Second-Quarter Saving Grace appeared first on Investor's Business Daily.

How Novartis' Laggard Business Was Its Second-Quarter Saving Grace

Novartis AG (NYSE:NVS ) Q2 2022 Results Conference Call July 19, 2022 8:00 AM ET Company Participants Samir Shah - Global Head, IR Vas Narasimhan - CEO Harry Kirsch - CFO Conference Call Participants Matthew Weston - Credit Suisse Tim Anderson - Wolfe Research Richard Vosser - JP Morgan Emmanuel Papadakis - Deutsche Bank Graham Parry - Bank of America Steve Scala - Cowen Florent Cespedes - Société Générale Emily Field - Barclays Simon Baker - Redburn Kerry Holford - Berenberg Seamus Fernandez - Guggenheim Securities Andrew Baum - Citi Laura Sutcliffe - UBS Keyur Parekh - Goldman Sachs Naresh Chouhan - Intron Health Sarita Kapila - Morgan Stanley Peter Welford - Jefferies Wimal Kapadia - Bernstein Richard Parkes - BNP Paribas Operator Good morning and good afternoon, and welcome to the Novartis Q2 2022 Results Release Conference Call and Live Webcast. Please note that during the presentation, all participants will be a listen-only mode and the conference is being recorded.

Novartis AG (NVS) CEO Vas Narasimhan on Q2 2022 Results - Earnings Call Transcript

Novartis (NVS) reports mixed results in the second quarter, as key brands maintain momentum but generic competition remains a drag.

Novartis (NVS) Q2 Earnings Beat, Revenues Miss Estimates

Novartis AG (NYSE: NVS) has reported a core EPS of $1.56 in Q2 FY22 compared to $1.66 a year ago, beating the consensus of $1.52. Net sales were $12.78 billion, down 1% Y/Y or up 5% at constant currency (CC), missing the consensus of $13.01 billion.

Novartis Posts Mixed Q2 Earnings, Expects Improved Earnings At Sandoz

Swiss drugmaker Novartis said earnings at its Sandoz unit, the maker of cheap generic drugs that might be put up for sale, would likely be flat this year, no longer expecting a decline, and added the strategic review was progressing as planned.

Novartis no longer expects earnings decline at under-review Sandoz unit

Ad hoc announcement pursuant to Art. 53 LR

Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY'22 Group guidance

Los Angeles, California--(Newsfile Corp. - July 15, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG ("Novartis" or "the Company") (NYSE: NVS) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Novartis announced on May 5, 2022, a "temporary, voluntary suspension of production...

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Novartis AG with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $NVS #NVS--The Schall Law Firm Encourages Investors in Novartis AG with Losses of $100,000 to Contact the Firm

News for Novartis Stock (NVS)